Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer
NCT05559177Phase 1Unknown
- Sponsor
- Shanghai Pudong Hospital
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in bladder cancer, sponsored by Shanghai Pudong Hospital. Primary endpoints: Clinical response rate at 24 months, Overall survival at 24 months and 1 more. Status: unknown.
02
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05559177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559177.